Production (Stage)
Protara Therapeutics, Inc.
TARA
$3.34
$0.2156.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.91M | -12.77M | -11.22M | -9.51M | -11.10M |
| Total Depreciation and Amortization | 83.00K | 82.00K | 84.00K | 83.00K | 83.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 930.00K | 884.00K | 854.00K | 1.31M | 1.40M |
| Change in Net Operating Assets | -3.81M | 2.50M | 1.85M | 436.00K | -771.00K |
| Cash from Operations | -14.71M | -9.31M | -8.43M | -7.69M | -10.38M |
| Capital Expenditure | -44.00K | 0.00 | -8.00K | -55.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -58.31M | 22.50M | -29.38M | 3.00M | 23.10M |
| Cash from Investing | -58.35M | 22.50M | -29.39M | 2.95M | 23.10M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.53M | 103.90M | 45.00M | 135.00K | -- |
| Repurchase of Common Stock | -185.00K | 0.00 | 0.00 | -7.00K | -76.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -614.00K | -6.05M | -45.00M | 41.96M | -- |
| Cash from Financing | 1.73M | 97.85M | 0.00 | 42.09M | -76.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -71.34M | 111.04M | -37.82M | 37.35M | 12.65M |